NEW YORK (GenomeWeb News) – DCN Diagnostics today announced a deal with Asahi Kasei Fibers for the distribution of Asahi's cellulose nanobead product in North America.
Additionally, DCN, formerly called Diagnostic Consulting Network, will be the preferred provider of original equipment manufacturing services to users of Asahi's product, called NanoAct, worldwide, except in Japan, where Asahi is based.
NanoAct products comprise a range of high-intensity colored beads, which can be multiplexed. They generate higher sensitivity, lower coefficients of variation, and better stability than other visual labels such as colloidal gold, DCN said.
"We believe that NanoAct will allow for the development of higher performing lateral flow tests," CDN President Brendan O'Farrell said in a statement. "Coupled with DCN's assay development, training and customer support capabilities, we believe that this product line will allow for product performance that can have significant impact in many markets."
Financial and other terms were not disclosed.